Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting Apr 20, 2016
Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual Meeting Apr 13, 2016
Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer Mar 29, 2016
Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress Mar 24, 2016
Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma Feb 8, 2016
Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 Feb 1, 2016
Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal Cancers Symposium Jan 25, 2016
New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition Jan 12, 2016
